# US 2020/0222510 A1 · Blood substitutes comprising hemoglobin and methods of making

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2020/0222510 A1
- Document ID: US20200222510A1
- Status: Published application
- Kind: A1
- Application number: 16/632,090
- Filed: 2018-07-17
- Published: 2020-07-16
- Earliest claimed: 2017-07-18
- Assignees: VirTech Bio, Inc.
- Applicants: Virtech Bio, Inc.
- Inventors: William Richard Light; Joseph Tucker
- Web page: https://patentgrep.com/patent/US20200222510A1

## CPC

- A61K 38/42: Haemoglobins; Myoglobins
- A61K 9/0026: {Blood substitute; Oxygen transporting formulations; Plasma extender}
- A61K 35/14: Blood; Artificial blood (perfluorocarbons A61K31/02; umbilical cord blood A61K35/51; haemoglobin A61K38/42)
- A61K 35/18: Erythrocytes (haemoglobin A61K38/42)
- A61P 7/08: Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock (artificial tears A61P27/04)
- C07K 14/805: Haemoglobins; Myoglobins
- C12N 5/0641: {Erythrocytes}
- A61M 1/0281: {Apparatus for treatment of blood or blood constituents prior to transfusion, e.g. washing, filtering or thawing}
- A61M 2202/0429: Red blood cells; Erythrocytes
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61M: DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY (introducing media into or onto the bodies of animals A61D7/00; means for inserting tampons A61F13/26; devices for administering food or medicines orally A61J; containers for collecting, storing or administering blood or medical fluids A61J1/05); DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY (surgery A61B; chemical aspects of surgical articles A61L); DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR {(Electrotherapy, e.g. producing anaesthesia by the use of alternating or intermittent currents A61N1/36021)}

## Abstract

Methods for making hemoglobin based blood substitute preparations and hemoglobin based blood substitute preparations. The methods involve preparing a low purity erythrocyte protein fraction comprising hemoglobin protein and endogenous non-hemoglobin protein complement, and chemically modifying the proteins in the protein fraction to form a cross-linked hemoglobin containing blood substitute preparation. The low purity erythrocyte protein preparation can contain from at least about 0.2% (mole/mole) up to about 20% (mole/mole) endogenous non-hemoglobin protein complement. At least about 90% (mole/mole) of the hemoglobin proteins can be cross-linked, so that the average molecular mass of cross-linked proteins comprising hemoglobin protein molecules in the preparation is at least about 300 kDa. The preparations can be used to prepare finished blood substitute formulations for in-vivo and ex-vivo use.

## Claims

### Claim 1

A method of preparing a blood substitute preparation comprising hemoglobin, the method comprising:
(i) isolating erythrocytes from blood;
(ii) isolating a low purity erythrocyte protein fraction comprising hemoglobin protein molecules and endogenous non-hemoglobin protein complement from the erythrocytes, the low purity erythrocyte protein fraction comprising from at least about 0.2% (mole/mole) up to about 20% (mole/mole) endogenous non-hemoglobin protein complement; and
(iii) contacting the low purity erythrocyte protein fraction with a reactant capable of chemically modifying the proteins in the protein fraction, the reactant thereby mediating the formation of cross-linked proteins comprising intermolecular cross-linkages between the hemoglobin protein molecules, and intermolecular cross-linkages between the hemoglobin protein molecules and the endogenous non-hemoglobin protein complement, to thereby form a blood substitute preparation.

### Claim 2 (depends on 1)

The method according to claim 1, wherein at least about 90% (mole/mole) of the hemoglobin protein molecules in the erythrocyte protein fraction is cross-linked, so that the average molecular mass of cross-linked proteins is at least about 300 kDa.

### Claim 3 (depends on 1)

The method according to claim 1, wherein at least about 90% (mole/mole) of the hemoglobin protein molecules in the erythrocyte protein fraction is cross-linked, so that the average molecular mass of cross-linked proteins is about 1,000 kDa.

### Claim 4 (depends on 1)

The method according to claim 1, wherein the endogenous non-hemoglobin protein complement comprises carbonic anhydrase, wherein the carbonic anhydrase comprises from at least about 0.2% (mole/mole) up to about 15% (mole/mole) of the endogenous non-hemoglobin protein complement.

### Claim 5 (depends on 1)

The method according to claim 1, wherein the reactant capable of modifying the proteins in the erythrocyte protein fraction is capable of forming reducible covalent cross-linkages.

### Claim 6 (depends on 1)

The method according to claim 1, wherein the reactant capable of modifying the proteins in the erythrocyte protein fraction is capable of forming reducible covalent cross-linkages, wherein the reducible covalent cross-linkages are Schiff bases.

### Claim 7 (depends on 1)

The method according to claim 1, wherein the reactant capable of chemically modifying the proteins in the erythrocyte protein fraction is a polyaldehyde, wherein the polyaldehyde is reacted under reaction conditions permitting a chemical reaction between aldehyde groups of the polyaldehyde and amino groups of the proteins to form a plurality of covalent intermolecular cross-linkages between the hemoglobin protein molecules, and between the hemoglobin protein molecules and the endogenous non-hemoglobin protein complement.

### Claim 8 (depends on 7)

The method according to claim 7, wherein following reaction with a polyaldehyde, the cross-linked proteins are reacted with a reducing agent to reduce the cross-linkages and form reduced cross-linkages.

### Claim 9 (depends on 7)

The method according to claim 7, wherein the polyaldehyde is glutaraldehyde.

### Claim 10 (depends on 6)

The method according to claim 6, wherein the reducible covalent-cross-linkages are Schiff bases, and the reduced covalent cross-linkages are secondary amines.

### Claim 11 (depends on 8)

The method according to claim 8, wherein the reducing agent is cyanoborohydride.

### Claim 12 (depends on 1)

The method according to claim 1, wherein the reactant capable of modifying the proteins in the erythrocyte protein fraction is a reactant capable of intermolecularly and intramolecularly cross-linking proteins in the erythrocyte protein fraction.

### Claim 13 (depends on 1)

The method according to claim 1, wherein the erythrocytes are isolated from blood by diafiltration.

### Claim 14 (depends on 1)

The method according to claim 1, wherein the erythrocytes are lysed by subjecting the erythrocytes to a hypotonic shock to obtain an erythrocyte lysate from which the low purity erythrocyte protein fraction is obtained.

### Claim 15 (depends on 1)

The method according to claim 1, wherein the low purity erythrocyte protein fraction is obtained by obtaining an erythrocyte lysate from the erythrocytes and subjecting the erythrocyte lysate to membrane filtration.

### Claim 16 (depends on 1)

The method according to claim 1, wherein the low purity erythrocyte protein fraction is obtained by obtaining an erythrocyte lysate from the erythrocytes and subjecting an erythrocyte lysate to tangential flow filtration.

### Claim 17 (depends on 1)

The method according to claim 1, wherein the method further includes the performance of a deoxygenation step, wherein the deoxygenation step is performed prior to step (i); following step (i) and prior to step (ii); following step (ii) and prior to step (iii); or following step (iii).

### Claim at position 18

-66. (canceled)
